- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07596524
Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
18. mai 2026 oppdatert av: JIANCHUN DUAN, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Analysis of Different Treatment Modalities and Clinical Outcomes in Advanced NSCLC Patients Progressing After First-Line Immune Checkpoint Inhibitor Therapy: An Observational Study Based on Real-World Data
The second-line treatment options in clinical practice for immunotherapy progress are complex.
Treatment strategies need to be selected based on different progression patterns.
It is difficult to simultaneously explore multiple treatment modalities through previous clinical studies.
Observational studies through real-world research can efficiently convert clinical practice data into clinical treatment evidence.
This study aims to observe the treatment patterns and clinical outcomes of advanced NSCLC patients who received first-line immunotherapy checkpoint inhibitor treatment after progression, in order to provide guidance for the second-line treatment options for patients with first-line immunotherapy progress.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Studietype
Observasjonsmessig
Registrering (Antatt)
300
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Jianchun Duan, M.D.
- Telefonnummer: +8610-87788029
- E-post: duanjianchun79@163.com
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100021
- Cancer Hospirtal, Chinese Academy of Medical Sciences
-
Ta kontakt med:
- Jianchun Duan, M.D.
- Telefonnummer: +8610-87788029
- E-post: duanjianchun79@163.com
-
-
Guangdong
-
Shenzhen, Guangdong, Kina, 518116
- Cancer Hospirtal, Chinese Academy of Medical Sciences, Shenzhen
-
Ta kontakt med:
- Jianchun Duan, M.D.
- Telefonnummer: +8613811259820
- E-post: duanjianchun79@163.com
-
-
Shanxi
-
Taiyuan, Shanxi, Kina, 030013
- Shanxi Provincial Cancer Hospital
-
Ta kontakt med:
- Jianchun Duan, M.D.
- Telefonnummer: +8613811259820
- E-post: duanjianchun79@163.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Hospital-based
Beskrivelse
Inclusion Criteria:
- Locally advanced or metastatic NSCLC that is not curable and confirmed by histological or cytological examination based on the 8th edition of AJCC staging.
- Previously received advanced first-line treatment based on immune checkpoint inhibitor drugs.
- Has a medical record of disease progression during the first-line treatment.
- Complete clinical and pathological data, such as age, gender, smoking history, primary tumor location, differentiation, metastatic site, and imaging and serological review as required.
Exclusion Criteria:
- First-line treatment with immune checkpoint inhibitor drugs was ≤ 2 cycles.
- Excluding patients with incomplete key baseline and treatment information.
- Have other potential factors that may affect the study results or result in the premature discontinuation, as determined by the investigator
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Observation
Patients with advanced NSCLC who have received standard first-line immune checkpoint inhibitor therapy and have experienced disease progression.
Retrospective case screening and collection were conducted, and follow-up observations were carried out.
|
The patients' second-line treatment received and the follow-up observations were retrospectively collected.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival
Tidsramme: Time from 2nd line treatment initiation to patient death from any cause, assessed up to 60 months
|
The overall survival time of the patients enrolled.
|
Time from 2nd line treatment initiation to patient death from any cause, assessed up to 60 months
|
|
Progression Free Survival
Tidsramme: Time from 2nd line treatment initiation to the first recorded progression event in the medical information system (radiographic report or physician assessment) or death from any cause, whichever occurs first, assessed up to 60 months
|
The time of disease progression free survival.
|
Time from 2nd line treatment initiation to the first recorded progression event in the medical information system (radiographic report or physician assessment) or death from any cause, whichever occurs first, assessed up to 60 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate
Tidsramme: From 2nd line treatment initiation, assessed up to 24 months
|
Overall response rate
|
From 2nd line treatment initiation, assessed up to 24 months
|
|
Disease control rate
Tidsramme: From 2nd line treatment initiation, assessed up to 24 months
|
Disease control rate
|
From 2nd line treatment initiation, assessed up to 24 months
|
|
Immune-related adverse events
Tidsramme: From 2nd line treatment initiation and before 3rd line treatment, assessed up to 24 months
|
Immune-related adverse events
|
From 2nd line treatment initiation and before 3rd line treatment, assessed up to 24 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Jianchun Duan, M.D., Cancer Hospirtal Chinese Academy of Medical Sciences
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. juli 2026
Primær fullføring (Antatt)
31. desember 2026
Studiet fullført (Antatt)
30. juni 2027
Datoer for studieregistrering
Først innsendt
12. mai 2026
Først innsendt som oppfylte QC-kriteriene
18. mai 2026
Først lagt ut (Faktiske)
19. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
19. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
18. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NCC-021875
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
IPD-planbeskrivelse
Whether IPD will be provided will be determined by the results of subsequent clinical trials.
At present, it is impossible to determine.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .